{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:30:10Z","timestamp":1793021410283,"version":"4.5.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T00:00:00Z","timestamp":1524182400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/nrrheum.2018.56","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T01:15:43Z","timestamp":1524186943000},"page":"290-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":374,"title":["Autoantibodies in myositis"],"prefix":"10.1038","volume":"14","author":[{"given":"Neil J.","family":"McHugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Tansley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,20]]},"reference":[{"key":"BFnrrheum201856_CR1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","volume":"73","author":"HB Larman","year":"2013","unstructured":"Larman, H. B. et al. Cytosolic 5\u2032-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann. Neurol. 73, 408\u2013418 (2013).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum201856_CR2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","volume":"73","author":"H Pluk","year":"2013","unstructured":"Pluk, H. et al. Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis. Ann. Neurol. 73, 397\u2013407 (2013).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum201856_CR3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","volume":"64","author":"E Trallero-Araguas","year":"2012","unstructured":"Trallero-Araguas, E. et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 64, 523\u2013532 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen, A. L. et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 63, 713\u2013721 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","volume":"280","author":"Z Betteridge","year":"2016","unstructured":"Betteridge, Z. & McHugh, N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J. Intern. Med. 280, 8\u201323 (2016).","journal-title":"J. Intern. Med."},{"key":"BFnrrheum201856_CR6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","volume":"84","author":"SL Tansley","year":"2017","unstructured":"Tansley, S. L. et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J. Autoimmun. 84, 55\u201364 (2017).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum201856_CR7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love, L. A. et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70, 360\u2013374 (1991).","journal-title":"Medicine"},{"key":"BFnrrheum201856_CR8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","volume":"201","author":"L Casciola-Rosen","year":"2005","unstructured":"Casciola-Rosen, L. et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J. Exp. Med. 201, 591\u2013601 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201856_CR9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.38863","volume":"67","author":"P Mohassel","year":"2015","unstructured":"Mohassel, P., Rosen, P., Casciola-Rosen, L., Pak, K. & Mammen, A. L. Expression of the dermatomyositis autoantigen transcription intermediary factor 1\u03b3 in regenerating muscle. Arthritis Rheumatol. 67, 266\u2013272 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201856_CR10","first-page":"820","volume":"34","author":"M Amaral Silva","year":"2016","unstructured":"Amaral Silva, M., Cogollo, E. & Isenberg, D. A. Why do patients with myositis die? A retrospective analysis of a single-centre cohort. Clin. Exp. Rheumatol. 34, 820\u2013826 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201856_CR11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","volume":"194","author":"C Johnson","year":"2016","unstructured":"Johnson, C. et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194, 733\u2013737 (2016).","journal-title":"Lung"},{"key":"BFnrrheum201856_CR12","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T Koga","year":"2012","unstructured":"Koga, T. et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51, 1278\u20131284 (2012).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","volume":"29","author":"A Vancsa","year":"2009","unstructured":"Vancsa, A. et al. Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients. Rheumatol. Int. 29, 989\u2013994 (2009).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum201856_CR14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","volume":"39","author":"R La Corte","year":"2006","unstructured":"La Corte, R., Lo Mo Naco, A., Locaputo, A., Dolzani, F. & Trotta, F. In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39, 249\u2013253 (2006).","journal-title":"Autoimmunity"},{"key":"BFnrrheum201856_CR15","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","volume":"63","author":"I Marie","year":"2011","unstructured":"Marie, I. et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 63, 3439\u20133447 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","volume":"23","author":"LJ Witt","year":"2016","unstructured":"Witt, L. J., Curran, J. J. & Strek, M. E. The diagnosis and treatment of antisynthetase syndrome. Clin. Pulm. Med. 23, 218\u2013226 (2016).","journal-title":"Clin. Pulm. Med."},{"key":"BFnrrheum201856_CR17","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/art.1780230802","volume":"23","author":"M Nishikai","year":"1980","unstructured":"Nishikai, M. & Reichlin, M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum. 23, 881\u2013888 (1980).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR18","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","volume":"138","author":"L Mescam-Mancini","year":"2015","unstructured":"Mescam-Mancini, L. et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 138, 2485\u20132492 (2015).","journal-title":"Brain"},{"key":"BFnrrheum201856_CR19","doi-asserted-by":"crossref","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","volume":"8","author":"Y Hamaguchi","year":"2013","unstructured":"Hamaguchi, Y. et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLOS ONE 8, e60442 (2013).","journal-title":"PLOS ONE"},{"key":"BFnrrheum201856_CR20","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3899\/jrheum.131223","volume":"41","author":"M Klein","year":"2014","unstructured":"Klein, M. et al. Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations. J. Rheumatol. 41, 1133\u20131139 (2014).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201856_CR21","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi, J. et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J. Rheumatol. 44, 1051\u20131057 (2017).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201856_CR22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","volume":"92","author":"LG Rider","year":"2013","unstructured":"Rider, L. G. et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 92, 223\u2013243 (2013).","journal-title":"Medicine"},{"key":"BFnrrheum201856_CR23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/acr.22212","volume":"66","author":"AM Huber","year":"2014","unstructured":"Huber, A. M. et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res. 66, 732\u2013740 (2014).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201856_CR24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11926-015-0548-6","volume":"17","author":"P Basharat","year":"2015","unstructured":"Basharat, P. & Christopher-Stine, L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr. Rheumatol. Rep. 17, 72 (2015).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrrheum201856_CR25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","volume":"69","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez, I. et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 69, 263\u2013270 (2017).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201856_CR26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/art.11484","volume":"50","author":"AH Kao","year":"2004","unstructured":"Kao, A. H., Lacomis, D., Lucas, M., Fertig, N. & Oddis, C. V. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 50, 209\u2013215 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR27","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","volume":"65","author":"GJ Hengstman","year":"2006","unstructured":"Hengstman, G. J. et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann. Rheum. Dis. 65, 1635\u20131638 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201856_CR28","first-page":"728","volume":"69","author":"S Suzuki","year":"2012","unstructured":"Suzuki, S. et al. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch. Neurol. 69, 728\u2013732 (2012).","journal-title":"Arch. Neurol."},{"key":"BFnrrheum201856_CR29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12969-017-0205-x","volume":"15","author":"EL Binns","year":"2017","unstructured":"Binns, E. L. et al. Effective induction therapy for anti-SRP associated myositis in childhood: a small case series and review of the literature. Pediatr. Rheumatol. 15, 77 (2017).","journal-title":"Pediatr. Rheumatol."},{"key":"BFnrrheum201856_CR30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","volume":"93","author":"Y Allenbach","year":"2014","unstructured":"Allenbach, Y. et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine 93, 150\u2013157 (2014).","journal-title":"Medicine"},{"key":"BFnrrheum201856_CR31","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/BOR.0000000000000106","volume":"26","author":"AL Mammen","year":"2014","unstructured":"Mammen, A. L. Necrotizing myopathies: beyond statins. Curr. Opin. Rheumatol. 26, 679\u2013683 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum201856_CR32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","volume":"44","author":"SL Tansley","year":"2017","unstructured":"Tansley, S. L. et al. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J. Rheumatol. 44, 488\u2013492 (2017).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201856_CR33","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","volume":"69","author":"T Kishi","year":"2017","unstructured":"Kishi, T. et al. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res. 69, 1088\u20131094 (2017).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201856_CR34","first-page":"787","volume":"56","author":"E Tiniakou","year":"2017","unstructured":"Tiniakou, E. et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology 56, 787\u2013794 (2017).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM199202063260602","volume":"326","author":"B Sigurgeirsson","year":"1992","unstructured":"Sigurgeirsson, B., Lindelof, B., Edhag, O. & Allander, E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N. Engl. J. Med. 326, 363\u2013367 (1992).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201856_CR36","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","volume":"49","author":"K Hoshino","year":"2010","unstructured":"Hoshino, K. et al. Anti-MDA5 and anti-TIF1-\u03b3 antibodies have clinical significance for patients with dermatomyositis. Rheumatology 49, 1726\u20131733 (2010).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","volume":"64","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto, M. et al. Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 64, 513\u2013522 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","volume":"71","author":"Y Ichimura","year":"2012","unstructured":"Ichimura, Y. et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann. Rheum. Dis. 71, 710\u2013713 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201856_CR39","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","volume":"65","author":"DF Fiorentino","year":"2013","unstructured":"Fiorentino, D. F. et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3. Arthritis Rheum. 65, 2954\u20132962 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR40","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda, J. et al. Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, and increased malignancy risk. Arthritis Care Res., 69, 1771\u20131776 (2017).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201856_CR41","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","volume":"69","author":"A Rogers","year":"2017","unstructured":"Rogers, A., Chung, L., Li, S., Casciola-Rosen, L. & Fiorentino, D. F. Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 69, 1909\u20131914 (2017).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201856_CR42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/gut.2009.178574","volume":"59","author":"G Kijanka","year":"2010","unstructured":"Kijanka, G. et al. Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut 59, 69\u201378 (2010).","journal-title":"Gut"},{"issue":"Suppl. 106","key":"BFnrrheum201856_CR43","first-page":"71","volume":"35","author":"AA Shah","year":"2017","unstructured":"Shah, A. A. et al. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clin. Exp. Rheumatol. 35 (Suppl. 106), 71\u201374 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201856_CR44","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/imj.13556","volume":"47","author":"K Dutton","year":"2017","unstructured":"Dutton, K. & Soden, M. Malignancy screening in autoimmune myositis amongst Australian rheumato-logists. Intern. Med. J. 47, 1367\u20131375 (2017).","journal-title":"Intern. Med. J."},{"key":"BFnrrheum201856_CR45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/ard.2005.040717","volume":"65","author":"GJ Hengstman","year":"2006","unstructured":"Hengstman, G. J. et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2\u03b2 antigen. Ann. Rheum. Dis. 65, 242\u2013245 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201856_CR46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10067-016-3453-0","volume":"36","author":"A Ceribelli","year":"2017","unstructured":"Ceribelli, A. et al. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin. Rheumatol. 36, 469\u2013475 (2017).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201856_CR47","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","volume":"139","author":"Y Allenbach","year":"2016","unstructured":"Allenbach, Y. et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 139, 2131\u20132135 (2016).","journal-title":"Brain"},{"key":"BFnrrheum201856_CR48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","volume":"19","author":"H Yang","year":"2017","unstructured":"Yang, H. et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res. Ther. 19, 259 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201856_CR49","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.rmed.2011.03.022","volume":"105","author":"K Watanabe","year":"2011","unstructured":"Watanabe, K. et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir. Med. 105, 1238\u20131247 (2011).","journal-title":"Respir. Med."},{"key":"BFnrrheum201856_CR50","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/rheumatology\/kew396","volume":"56","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal, R. et al. Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis. Rheumatology 56, 384\u2013389 (2017).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","volume":"73","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal, R. et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann. Rheum. Dis. 73, 227\u2013232 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201856_CR52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","volume":"12","author":"B Hervier","year":"2012","unstructured":"Hervier, B. et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun. Rev. 12, 210\u2013217 (2012).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201856_CR53","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","volume":"13","author":"JC Lega","year":"2014","unstructured":"Lega, J. C. et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun. Rev. 13, 883\u2013891 (2014).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201856_CR54","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.autrev.2007.01.013","volume":"6","author":"M Mahler","year":"2007","unstructured":"Mahler, M. & Raijmakers, R. Novel aspects of autoantibodies to the PM\/Scl complex: clinical, genetic and diagnostic insights. Autoimmun. Rev. 6, 432\u2013437 (2007).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201856_CR55","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato, S. et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 60, 2193\u20132200 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR56","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono, T. et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51, 1563\u20131570 (2012).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR57","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","volume":"158","author":"I Kobayashi","year":"2011","unstructured":"Kobayashi, I. et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J. Pediatr. 158, 675\u2013677 (2011).","journal-title":"J. Pediatr."},{"key":"BFnrrheum201856_CR58","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","volume":"54","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi, N. et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology 54, 784\u2013791 (2015).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino, D., Chung, L., Zwerner, J., Rosen, A. & Casciola-Rosen, L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J. Am. Acad. Dermatol. 65, 25\u201334 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum201856_CR60","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","volume":"65","author":"JC Hall","year":"2013","unstructured":"Hall, J. C. et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 65, 1307\u20131315 (2013).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201856_CR61","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","volume":"68","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia, S., Oddis, C. V., Sato, S., Kuwana, M. & Aggarwal, R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res. 68, 689\u2013694 (2016).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201856_CR62","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","volume":"16","author":"SL Tansley","year":"2014","unstructured":"Tansley, S. L. et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res. Ther. 16, R138 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201856_CR63","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22498","volume":"67","author":"NS Narang","year":"2015","unstructured":"Narang, N. S., Casciola-Rosen, L., Li, S., Chung, L. & Fiorentino, D. F. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res. 67, 667\u2013672 (2015).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201856_CR64","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","volume":"72","author":"DF Fiorentino","year":"2015","unstructured":"Fiorentino, D. F. et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis. J. Am. Acad. Dermatol. 72, 449\u2013455 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum201856_CR65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11926-014-0465-0","volume":"16","author":"EE Bailey","year":"2014","unstructured":"Bailey, E. E. & Fiorentino, D. F. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr. Rheumatol. Rep. 16, 465 (2014).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrrheum201856_CR66","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","volume":"68","author":"ZE Betteridge","year":"2009","unstructured":"Betteridge, Z. E. et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann. Rheum. Dis. 68, 1621\u20131625 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201856_CR67","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato, S. et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52, 1571\u20131576 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR68","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.39466","volume":"68","author":"GE Habers","year":"2016","unstructured":"Habers, G. E. et al. Association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis. Arthritis Rheumatol. 68, 761\u2013768 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201856_CR69","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","volume":"53","author":"SL Tansley","year":"2014","unstructured":"Tansley, S. L. et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology 53, 2204\u20132208 (2014).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR70","first-page":"303","volume":"35","author":"M Fredi","year":"2017","unstructured":"Fredi, M. et al. Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. Clin. Exp. Rheumatol. 35, 303\u2013308 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201856_CR71","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/ar3822","volume":"14","author":"A Ceribelli","year":"2012","unstructured":"Ceribelli, A. et al. Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis. Arthritis Res. Ther. 14, R97 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201856_CR72","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamadermatol.2013.10416","volume":"150","author":"A Valenzuela","year":"2014","unstructured":"Valenzuela, A., Chung, L., Casciola-Rosen, L. & Fiorentino, D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol. 150, 724\u2013729 (2014).","journal-title":"JAMA Dermatol."},{"key":"BFnrrheum201856_CR73","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","volume":"134","author":"O Benveniste","year":"2011","unstructured":"Benveniste, O. et al. Long-term observational study of sporadic inclusion body myositis. Brain 134, 3176\u20133184 (2011).","journal-title":"Brain"},{"key":"BFnrrheum201856_CR74","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","volume":"76","author":"JB Lilleker","year":"2017","unstructured":"Lilleker, J. B. et al. Cytosolic 5\u2032-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann. Rheum. Dis. 76, 862\u2013868 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201856_CR75","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","volume":"75","author":"MK Herbert","year":"2016","unstructured":"Herbert, M. K. et al. Disease specificity of autoantibodies to cytosolic 5\u2032-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann. Rheum. Dis. 75, 696\u2013701 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201856_CR76","first-page":"223","volume":"44","author":"R Aggarwal","year":"2016","unstructured":"Aggarwal, R. et al. A negative antinuclear antibody does not indicate autoantibody negativity in myositis: role of anticytoplasmic antibody as a screening test for antisynthetase syndrome. J. Rheumatol. 44, 223\u2013229 (2016).","journal-title":"Rheumatol."},{"key":"BFnrrheum201856_CR77","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pathol.2016.03.012","volume":"48","author":"C Bundell","year":"2016","unstructured":"Bundell, C., Rojana-Udomsart, A., Mastaglia, F., Hollingsworth, P. & McLean-Tooke, A. Diagnostic performance of a commercial immunoblot assay for myositis antibody testing. Pathology 48, 363\u2013366 (2016).","journal-title":"Pathology"},{"key":"BFnrrheum201856_CR78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","volume":"433","author":"I Cavazzana","year":"2016","unstructured":"Cavazzana, I. et al. Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J. Immunol. Methods 433, 1\u20135 (2016).","journal-title":"J. Immunol. Methods"},{"key":"BFnrrheum201856_CR79","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.md.0000217525.82287.eb","volume":"85","author":"TP O'Hanlon","year":"2006","unstructured":"O'Hanlon, T. P. et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine 85, 111\u2013127 (2006).","journal-title":"Medicine"},{"key":"BFnrrheum201856_CR80","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/kep248","volume":"48","author":"H Chinoy","year":"2009","unstructured":"Chinoy, H. et al. HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology 48, 1213\u20131217 (2009).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR81","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/gene.2015.28","volume":"16","author":"FW Miller","year":"2015","unstructured":"Miller, F. W. et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes Immun. 16, 470\u2013480 (2015).","journal-title":"Genes Immun."},{"key":"BFnrrheum201856_CR82","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","volume":"75","author":"S Rothwell","year":"2016","unstructured":"Rothwell, S. et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann. Rheum. Dis. 75, 1558\u20131566 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201856_CR83","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.34657","volume":"64","author":"T Gono","year":"2012","unstructured":"Gono, T. et al. Association of HLA-DRB1*0101\/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 64, 3736\u20133740 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR84","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","volume":"54","author":"IN Targoff","year":"2006","unstructured":"Targoff, I. N. et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 54, 3682\u20133689 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR85","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.20662","volume":"64","author":"AL Mammen","year":"2012","unstructured":"Mammen, A. L. et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res. 64, 1233\u20131237 (2012).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201856_CR86","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/art.22205","volume":"54","author":"TP O'Hanlon","year":"2006","unstructured":"O'Hanlon, T. P. et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum. 54, 3670\u20133681 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR87","doi-asserted-by":"crossref","first-page":"34976","DOI":"10.1074\/jbc.M805383200","volume":"283","author":"CJ Burd","year":"2008","unstructured":"Burd, C. J., Kinyamu, H. K., Miller, F. W. & Archer, T. K. UV radiation regulates Mi-2 through protein translation and stability. J. Biol. Chem. 283, 34976\u201334982 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum201856_CR88","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.24702","volume":"60","author":"LA Love","year":"2009","unstructured":"Love, L. A. et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 60, 2499\u20132504 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR89","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/art.11090","volume":"48","author":"S Okada","year":"2003","unstructured":"Okada, S. et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 48, 2285\u20132293 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR90","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1002\/art.21198","volume":"52","author":"K Sarkar","year":"2005","unstructured":"Sarkar, K. et al. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum. 52, 2433\u20132438 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR91","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5551\/jat.12.121","volume":"12","author":"S Morikawa","year":"2005","unstructured":"Morikawa, S. et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J. Atheroscler. Thromb. 12, 121\u2013131 (2005).","journal-title":"J. Atheroscler. Thromb."},{"key":"BFnrrheum201856_CR92","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1097\/MD.0000000000000416","volume":"94","author":"Y Watanabe","year":"2015","unstructured":"Watanabe, Y. et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine 94, e416 (2015).","journal-title":"Medicine"},{"key":"BFnrrheum201856_CR93","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/annrheumdis-2011-200182","volume":"71","author":"H Chinoy","year":"2012","unstructured":"Chinoy, H. et al. Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann. Rheum. Dis. 71, 961\u2013965 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201856_CR94","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.24977","volume":"60","author":"AL Mammen","year":"2009","unstructured":"Mammen, A. L. et al. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 60, 3784\u20133793 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR95","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","volume":"343","author":"CG Joseph","year":"2014","unstructured":"Joseph, C. G. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343, 152\u2013157 (2014).","journal-title":"Science"},{"key":"BFnrrheum201856_CR96","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","volume":"57","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez, I. et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology 57, 388\u2013396 (2018).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR97","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fimmu.2017.00992","volume":"8","author":"A Aussy","year":"2017","unstructured":"Aussy, A., Boyer, O. & Cordel, N. Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front. Immunol. 8, 992 (2017).","journal-title":"Front. Immunol."},{"key":"BFnrrheum201856_CR98","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","volume":"56","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez, I. et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology 56, 999\u20131007 (2017).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR99","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","volume":"55","author":"R Aggarwal","year":"2016","unstructured":"Aggarwal, R. et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology 55, 991\u2013999 (2016).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR100","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s10067-015-3059-y","volume":"34","author":"E Vermaak","year":"2015","unstructured":"Vermaak, E., Tansley, S. L. & McHugh, N. J. The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clin. Rheumatol. 34, 2089\u20132095 (2015).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201856_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CDLI.2.1.1-9.1995","volume":"2","author":"LG Rider","year":"1995","unstructured":"Rider, L. G. & Miller, F. W. Laboratory evaluation of the inflammatory myopathies. Clin. Diagn. Lab. Immunol. 2, 1\u20139 (1995).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"BFnrrheum201856_CR102","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","volume":"56","author":"KB Stone","year":"2007","unstructured":"Stone, K. B. et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 56, 3125\u20133131 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR103","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/rheumatology\/ker408","volume":"51","author":"Y Muro","year":"2012","unstructured":"Muro, Y., Sugiura, K., Hoshino, K. & Akiyama, M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM\/interstitial lung disease during disease remission. Rheumatology 51, 800\u2013804 (2012).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR104","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","volume":"13","author":"M Mahler","year":"2014","unstructured":"Mahler, M., Miller, F. W. & Fritzler, M. J. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun. Rev. 13, 367\u2013371 (2014).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201856_CR105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","volume":"5","author":"M Reichlin","year":"1976","unstructured":"Reichlin, M. & Mattioli, M. Description of a serological reaction characteristic of polymyositis. Clin. Immunol. Immunopathol. 5, 12\u201320 (1976).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"BFnrrheum201856_CR106","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1084\/jem.160.2.420","volume":"160","author":"MB Mathews","year":"1984","unstructured":"Mathews, M. B., Reichlin, M., Hughes, G. R. & Bernstein, R. M. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J. Exp. Med. 160, 420\u2013434 (1984).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201856_CR107","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1073\/pnas.83.24.9507","volume":"83","author":"WH Reeves","year":"1986","unstructured":"Reeves, W. H., Nigam, S. K. & Blobel, G. Human autoantibodies reactive with the signal-recognition particle. Proc. Natl Acad. Sci. USA 83, 9507\u20139511 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201856_CR108","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.163.5.1281","volume":"163","author":"CC Bunn","year":"1986","unstructured":"Bunn, C. C., Bernstein, R. M. & Mathews, M. B. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J. Exp. Med. 163, 1281\u20131291 (1986).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201856_CR109","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/art.1780350718","volume":"35","author":"IN Targoff","year":"1992","unstructured":"Targoff, I. N., Trieu, E. P., Plotz, P. H. & Miller, F. W. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 35, 821\u2013830 (1992).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR110","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1172\/JCI116493","volume":"91","author":"IN Targoff","year":"1993","unstructured":"Targoff, I. N., Trieu, E. P. & Miller, F. W. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J. Clin. Invest. 91, 2556\u20132564 (1993).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201856_CR111","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.4049\/jimmunol.162.4.2315","volume":"162","author":"M Hirakata","year":"1999","unstructured":"Hirakata, M. et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J. immunol. 162, 2315\u20132320 (1999).","journal-title":"J. immunol."},{"key":"BFnrrheum201856_CR112","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1002\/art.20784","volume":"52","author":"L Hashish","year":"2005","unstructured":"Hashish, L., Trieu, E. P., Sadanandan, P. & Targoff, I. N. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome. Arthritis Rheumatol. 52, S312 (2005).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201856_CR113","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kem045","volume":"46","author":"Z Betteridge","year":"2007","unstructured":"Betteridge, Z., Gunawardena, H., North, J., Slinn, J. & McHugh, N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 46, 1005\u20131008 (2007).","journal-title":"Rheumatology"},{"key":"BFnrrheum201856_CR114","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/art.22862","volume":"56","author":"Z Betteridge","year":"2007","unstructured":"Betteridge, Z., Gunawardena, H., North, J., Slinn, J. & McHugh, N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 56, 3132\u20133137 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR115","first-page":"S787","volume":"56","author":"IN Targoff","year":"2007","unstructured":"Targoff, I. N., Trieu, E. P., Levy-Neto, M. & Oddis, C. V. Sera with autoantibodies to MJ antigen react with NXP2. Arthritis Rheumatol. 56, S787 (2007).","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl.","key":"BFnrrheum201856_CR116","first-page":"139","volume":"40","author":"C Oddis","year":"1997","unstructured":"Oddis, C. et al. Clinical and serological characterisation of the anti\u2013MJ antibody in childhood myositis [abstract]. Arthritis Rheum. 40 (Suppl.), 139 (1997).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201856_CR117","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/ar1862","volume":"8","author":"H Chinoy","year":"2006","unstructured":"Chinoy, H. et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific\/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res. Ther. 8, R13 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201856_CR118","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/art.1780390521","volume":"39","author":"R Mierau","year":"1996","unstructured":"Mierau, R. et al. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum. 39, 868\u2013876 (1996).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.56.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.56","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrrheum.2018.56","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.56.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T02:18:13Z","timestamp":1693621093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2018.56"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,20]]},"references-count":118,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["BFnrrheum201856"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2018.56","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,20]]},"assertion":[{"value":"20 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}